http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2636966-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a07db4645376fd772515472951beabc0
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-91
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-63
filingDate 1989-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1990-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber FR-2636966-A1
titleOfInvention OBTAINING ORGANIC PROTEOCRYSTAL "CHRYSOEVERINE"
abstract An organic proteocrystal derived, by biotechnological manipulation, from the species Samia Cyntia, which communicates anti-growth characteristics to certain human pathogenic conditions. The crystal is offered as a base for the pharmaceutical manufacture of antineoplastic and anti-viral agents. Crystal is well tolerated in human systems and is not interactive with homeo tissue. The crystal's mechanism of action takes place at the genetic level by causing the growth of certain oncological and viral processes to stop. This process also stimulates the production of genetic agents systematically to produce a capacity for self-vaccination. This crystal is cruciform and presents a rare quality of quadrupolarity. Other uses include a filtering agent for free radicals and other antigens and as a basic substance for research concerning the nature of growth factors, anti-growth factors, genetic alteration factors and the nature of cell polarity. .
priorityDate 1989-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2612940-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID402
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707758
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559526

Total number of triples: 22.